Helicobacter Pylori Eradication, Acid Suppression and Upper GI Endoscopy
This community focuses on the diagnosis and treatment of Helicobacter pylori infection, the management of acid-related disorders such as gastroesophageal reflux disease, and the endoscopic evaluation of upper gastrointestinal conditions.
The work centers on antibiotic regimens, specifically bismuth-based quadruple therapy and dual therapies, to eradicate H. pylori and prevent gastric cancer. It also covers the clinical application of proton pump inhibitors and potassium-competitive acid blockers for acid suppression. Endoscopic procedures, including peroral endoscopic myotomy for achalasia and diagnostic endoscopy for reflux and dysphagia, form a significant portion of the research. The literature includes numerous randomized controlled trials, systematic reviews, and meta-analyses evaluating the efficacy and safety of these treatments, alongside studies on antibiotic resistance and the synthesis of bismuth compounds.
The community is most heavily represented in bismuth research, accounting for 6.6% of all bismuth-related papers, with 6,148 papers in this group. It also contributes 3.2% of antimony research (1,445 papers) and 2.3% of barium research (2,308 papers).
There are 26,262 papers in this community, published primarily in Gastroenterology, Gut, and Phosphorus, Sulfur, and Silicon and the Related Elements.
Recent work continues to focus on H. pylori management, including the Taipei Global Consensus II on screening and eradication for gastric cancer prevention, and new randomized trials evaluating vonoprazan-tetracycline dual regimens and bismuth quadruple therapy. Guidelines for gastroparesis and functional esophageal disorders are also being updated.